- Guide to PHARMACOLOGY
Synonyms: 4SC-101 | IMU-838 (vidofludimus calcium) | SC12267
Compound class: Synthetic organic
Comment: Vidofludimus (4SC-101) is a small molecule dihydroorotate dehydrogenase (DHOD) inhibitor that was developed for immunosuppressive potential . It has an improved toxicity profile in comparison to the clinically used disease modifying anti-rheumatic drug (DMARD) leflunomide.
Since its initial development, vidofludimus has been superceded by IMU-838 which is an orally active polymorph of vidofludimus calcium (PubChem CID: 56944639) .
SARS-CoV-2 and COVID-19: The target of vidofludimus, DHODH, plays a role in the metabolism of activated T cells and B cells to regulate the inflammatory response. It has been advanced to clinical trial in patients with severe COVID-19, to as attempt to block the release of pro-inflammatory cytokines and temper hyperinflammation in these patients.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|Phase 2 clinical trials designed to determine the clinical efficacy of the original formulation, 4SC-101 in inflammatory bowel disease and rheumatoid arthritis have been completed. Published results from the IBD trial NCT00820365 are indicative of clinical efficacy in this indication . Vidofludimus missed the primary endpoint in a Phase 2b RA trial. A new formulation of vidofludimus known as IMU-838 has replaced the original agent, and this is under active evaluation for clinical efficacy in ulcerative colitis, primary sclerosing cholangitis, multiple sclerosis  and COVID-19.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04379271||A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)||Phase 2/Phase 3 Interventional||Immunic AG|
|NCT03722576||Vidofludimus Calcium for Primary Sclerosing Cholangitis||Phase 2 Interventional||Mayo Clinic|
|NCT03341962||Phase 2 Dose-finding IMU-838 for Ulcerative Colitis||Phase 2 Interventional||Immunic AG|
|NCT03846219||MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)||Phase 2 Interventional||Immunic AG||Immunic have informally reported that IMU-838 (vidofludimus calcium, treatment for 6 months) has significant anti-demyelination efficacy in patients with RR MS (determined by MRI as a decrease in brain lesions). This trial includes the availability of an extension phase through which patients can choose to keep receiving treatment for up to nine and a half years.|